Compare FBIN & ACLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FBIN | ACLX |
|---|---|---|
| Founded | 1988 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2B | 6.7B |
| IPO Year | 2011 | 2022 |
| Metric | FBIN | ACLX |
|---|---|---|
| Price | $42.11 | $115.02 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 11 | 15 |
| Target Price | $54.60 | ★ $115.85 |
| AVG Volume (30 Days) | ★ 2.9M | 860.6K |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.51% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.47 | N/A |
| Revenue | ★ $4,463,200,000.00 | $22,286,000.00 |
| Revenue This Year | $2.68 | $342.39 |
| Revenue Next Year | $3.60 | $170.71 |
| P/E Ratio | $16.73 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $36.07 | $47.86 |
| 52 Week High | $64.84 | $115.13 |
| Indicator | FBIN | ACLX |
|---|---|---|
| Relative Strength Index (RSI) | 52.36 | 80.04 |
| Support Level | $36.07 | $66.06 |
| Resistance Level | $53.19 | N/A |
| Average True Range (ATR) | 1.65 | 0.12 |
| MACD | 0.79 | -0.80 |
| Stochastic Oscillator | 94.67 | 77.66 |
Fortune Brands Innovations is a leading home and security products company that has three reportable segments. The company's $2.6 billion water segment, led by the Moen brand, sells faucets, showers, and other plumbing fixtures; the $1.4 billion outdoors segment primarily sells entry doors under the Therma-Tru brand name and Fiberon-branded patio decking; and the $700 million security segment sells locks and other security devices under the Master Lock, SentrySafe, Yale, and August brand names.
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.